GO:0042800 histone H3K4 methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042800 describes the enzymatic activity that transfers methyl groups from S-adenosyl-L-methionine to lysine 4 of histone H3, generating S-adenosyl-L-homocysteine and mono-, di-, or trimethylated H3K4.
• H3K4 methylation is a conserved chromatin mark enriched at active promoters and enhancers, and its genome-wide distribution has been mapped at high resolution in human cells.
• The activity is carried out by multi-subunit COMPASS-like complexes whose catalytic subunits include KMT2A, KMT2B, KMT2C, KMT2D, KMT2E, KMT2F, KMT2G, and KMT2H in humans.
• Methyltransferase activity is regulated by associated subunits, histone ubiquitination, and sensing of unmodified histone H3, allowing context-dependent control.
• Dysregulation of H3K4 methyltransferases is linked to cancer, developmental disorders, and neurological disease, making these enzymes attractive therapeutic targets.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of H3K4 methyltransferase function in health and disease.
Description
Histone H3 lysine 4 (H3K4) methylation is one of the most intensively studied chromatin modifications in eukaryotes. The enzymatic activity responsible for depositing this mark is annotated in the Gene Ontology as GO:0042800, histone H3K4 methyltransferase activity, a molecular function that catalyzes the transfer of up to three methyl groups from S-adenosyl-L-methionine to lysine 4 of histone H3. High-resolution profiling has shown that H3K4 methylation states are distributed in distinct patterns across the human genome, with H3K4me3 concentrated at active promoters and H3K4me1 enriched at enhancers. Because these marks correlate with transcriptionally permissive chromatin, the enzymes that write them are central to gene regulation, development, and disease. Researchers study GO:0042800 to understand how chromatin states are established and inherited, how transcriptional programs are controlled, and how mutations in H3K4 methyltransferases contribute to cancer and developmental disorders. The activity is not performed by isolated enzymes but by large multi-subunit complexes that include catalytic SET-domain proteins and accessory subunits that modulate substrate recognition and catalytic output. This complexity makes H3K4 methyltransferase activity a paradigm for studying how enzymatic function is regulated within chromatin. From a translational perspective, pharmacological and genetic manipulation of H3K4 methyltransferase activity is being explored for epigenetic therapy, and the clinical challenges of targeting histone lysine methylation are increasingly recognized. Understanding the precise catalytic mechanism, the composition of the responsible complexes, and the consequences of loss- or gain-of-function mutations is therefore essential for both basic and applied research.
histone H3K4 methyltransferase activity At A Glance
| GO ID | GO:0042800 |
|---|---|
| GO term | histone H3K4 methyltransferase activity |
| Ontology | molecular_function |
| Synonym | histone H3K4 methylase activity; histone-H3K4 methyltransferase activity; histone H3 lysine 4-specific methyltransferase activity; histone lysine N-methyltransferase activity (H3-K4 specific); histone methylase activity (H3-K4 specific); histone methyltransferase activity (H3-K4 specific) |
| Major function | Catalyzes the transfer of up to three methyl groups from S-adenosyl-L-methionine to lysine 4 of histone H3, producing S-adenosyl-L-homocysteine and mono-, di-, or trimethylated H3K4. |
| Substrate | Histone H3, specifically lysine 4; methyl donor is S-adenosyl-L-methionine. |
| Products | S-adenosyl-L-homocysteine and histone H3 N6-methyl-L-lysine at position 4. |
| Representative catalytic subunits | KMT2A, KMT2B, KMT2C, KMT2D, KMT2E, KMT2F, KMT2G, KMT2H in humans. |
| Associated complexes | COMPASS-like multi-subunit complexes containing SET-domain catalytic subunits and accessory proteins. |
What Is GO:0042800?
GO:0042800, histone H3K4 methyltransferase activity, is defined as the catalysis of the reaction in which S-adenosyl-L-methionine and histone H3 L-lysine at position 4 are converted to S-adenosyl-L-homocysteine and histone H3 N6-methyl-L-lysine at position 4. The reaction can add up to three methyl groups to the same lysine residue, producing mono-, di-, and trimethylated H3K4. This activity is a molecular function that resides in SET-domain-containing catalytic subunits of COMPASS-like complexes and is directed toward a specific histone substrate, H3, at a defined residue, K4.
Why Is histone H3K4 methyltransferase activity Important in Cell Biology?
Histone H3K4 methyltransferase activity is a cornerstone of epigenetic regulation because it deposits a mark that is strongly associated with active transcription and open chromatin. Genome-wide maps of H3K4 methylation have revealed that distinct methylation states demarcate promoters, enhancers, and gene bodies, providing a framework for understanding how transcription is controlled. Because the enzymes that carry out this activity are frequently mutated or dysregulated in human disease, they are important both as mechanistic models of chromatin regulation and as potential therapeutic targets. Studying GO:0042800 therefore connects basic enzymology to developmental biology, cancer biology, and neurobiology.
• H3K4 methylation is a conserved epigenetic mark that correlates with active transcription and open chromatin.
• The activity is essential for normal development, and mutations in H3K4 methyltransferases cause developmental disorders.
• KMT2C and KMT2D are frequently mutated in cancer, linking H3K4 methyltransferase activity to tumorigenesis.
• H3K4 methylation states are dynamically regulated and can be influenced by replication and checkpoint signaling.
• Histone ubiquitination and unmodified histone H3 tails can modulate methyltransferase activity, revealing layers of regulation.
• Pharmacological targeting of histone lysine methylation is an active area of epigenetic therapy with clinical challenges.
• H3K4 methyltransferase complexes integrate signals from associated subunits to achieve substrate specificity.
• The activity is required for proper gene expression homeostasis during DNA replication.
• Dysregulation of H3K4 methylation is implicated in neurological and neurodevelopmental conditions.
• CRISPR models of H3K4 methyltransferase genes enable causal testing of their roles in disease.
What Happens During histone H3K4 methyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme first finds and holds onto the histone H3 protein at the right spot.
The catalytic subunit of a COMPASS-like complex recognizes the histone H3 tail, positioning lysine 4 in the active site. Accessory subunits and associated factors contribute to substrate selection and can sense the modification state of the histone tail; for example, Caf1 regulates the histone methyltransferase activity of Ash1 by sensing unmodified histone H3. Histone ubiquitination can also influence methyltransferase activity through diverse modes of regulation. This step ensures that methylation occurs at the correct residue and in the appropriate chromatin context.
Methyl group transfer from S-adenosyl-L-methionine
In simple terms: The enzyme takes a methyl group from a donor molecule and attaches it to lysine 4 of histone H3.
The catalytic SET domain binds the cofactor S-adenosyl-L-methionine and transfers its methyl group to the epsilon-amino group of histone H3 lysine 4, releasing S-adenosyl-L-homocysteine. The reaction can proceed up to three times on the same lysine, generating H3K4me1, H3K4me2, and H3K4me3. The distribution of these methylation states across the human genome has been mapped at high resolution, showing distinct patterns at promoters and enhancers.
Product release and chromatin context
In simple terms: After adding the methyl mark, the enzyme lets go, leaving the modified histone in place.
Following catalysis, the methylated histone H3 remains incorporated in chromatin, where the new mark can be recognized by reader proteins that influence transcription. The overall levels and patterns of H3K4 methylation are shaped by the balance of methyltransferase and demethylase activities, and by replication-coupled processes that maintain expression homeostasis. High-resolution profiling has revealed that H3K4me3 is enriched at active promoters while H3K4me1 is more prominent at enhancers.
Regulation by complex subunits and cellular signals
In simple terms: Other proteins and cellular signals can turn the enzyme up or down.
The activity of H3K4 methyltransferases is not constitutive; it is regulated by associated subunits, post-translational modifications of histones, and cellular signaling. For instance, histone ubiquitination can modulate methyltransferase activity in diverse ways, and the Ash1 methyltransferase is regulated by Caf1 in response to unmodified histone H3. During DNA replication, the replication checkpoint stabilizes epigenetic control of expression homeostasis, indirectly influencing H3K4 methylation patterns. These regulatory layers allow cells to tailor H3K4 methylation to specific developmental and environmental contexts.
Key Genes Involved in GO:0042800 histone H3K4 methyltransferase activity
The following genes encode catalytic subunits or key components of H3K4 methyltransferase complexes and are central to research on GO:0042800.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KMT2A | Catalytic subunit of COMPASS-like complex; deposits H3K4 methylation | Frequently studied in leukemia and developmental disorders |
| KMT2B | Catalytic subunit of COMPASS-like complex; deposits H3K4 methylation | Linked to neurological and developmental phenotypes |
| KMT2C | Catalytic subunit of COMPASS-like complex; deposits H3K4 methylation | Tumor suppressor role; frequently mutated in cancer |
| KMT2D | Catalytic subunit of COMPASS-like complex; deposits H3K4 methylation | Mutated in Kabuki syndrome and cancer |
| KMT2E | Catalytic subunit of COMPASS-like complex; deposits H3K4 methylation | Implicated in neurodevelopmental disorders |
| KMT2F | Catalytic subunit of SET1/COMPASS complex; deposits H3K4 methylation | Model for studying H3K4me3 at promoters |
| KMT2G | Catalytic subunit of SET1/COMPASS complex; deposits H3K4 methylation | Model for studying H3K4me3 at promoters |
| KMT2H | Catalytic subunit of COMPASS-like complex; deposits H3K4 methylation | Associated with developmental regulation |
| ASH1L | Histone H3K4 methyltransferase regulated by Caf1 | Model for studying regulation by unmodified H3 |
| SETD1A | Catalytic subunit of SET1/COMPASS complex | Studied in transcription and development |
| SETD1B | Catalytic subunit of SET1/COMPASS complex | Studied in transcription and development |
| WDR5 | Core subunit of COMPASS-like complexes; scaffolds catalytic subunits | Target for probing complex assembly |
| RBBP5 | Core subunit of COMPASS-like complexes; stimulates methyltransferase activity | Target for probing complex assembly |
| ASH2L | Core subunit of COMPASS-like complexes; stimulates methyltransferase activity | Target for probing complex assembly |
| DPY30 | Core subunit of COMPASS-like complexes; stabilizes complex | Target for probing complex assembly |
| Caf1 | Regulates Ash1 methyltransferase by sensing unmodified histone H3 | Model for substrate sensing |
| H3-3A | Histone H3 variant that can be methylated at K4 | Substrate for methylation assays |
| H3-3B | Histone H3 variant that can be methylated at K4 | Substrate for methylation assays |
How Is histone H3K4 methyltransferase activity Regulated?
H3K4 methyltransferase activity is regulated at multiple levels. The catalytic SET domain requires association with core subunits such as WDR5, RBBP5, ASH2L, and DPY30 for optimal activity and substrate specificity. Histone ubiquitination can modulate methyltransferase activity through diverse mechanisms, providing crosstalk between different chromatin modifications. In addition, the Ash1 methyltransferase is regulated by Caf1, which senses unmodified histone H3, illustrating how the modification state of the substrate can feed back on enzyme activity. During DNA replication, the replication checkpoint stabilizes epigenetic control of expression homeostasis, which can influence H3K4 methylation patterns. Finally, pharmacological and genetic studies have shown that histone lysine methylation is subject to complex regulation in disease contexts, with clinical challenges for therapeutic targeting.
histone H3K4 methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KMT2C | Cancer; tumor suppressor role | Knockout cell lines and xenografts |
| KMT2D | Kabuki syndrome; cancer | Knock-in of patient mutations in cell lines |
| KMT2A | Leukemia; developmental disorders | Knockout and point-mutation models |
| KMT2B | Neurological and developmental phenotypes | Knockout and knock-in models |
| ASH1L | Regulation by unmodified H3; developmental roles | Point-mutation and knockout models |
Cancer
Mutations and dysregulation of H3K4 methyltransferases are common in human cancers. KMT2C is frequently mutated in multiple tumor types and has been proposed to act as a tumor suppressor, with its loss associated with altered chromatin states and gene expression. KMT2D is also recurrently mutated in cancer and in Kabuki syndrome, linking H3K4 methylation to both developmental and oncogenic processes. Epigenetic therapies targeting histone lysine methylation are being explored, although complex mechanisms and clinical challenges remain.
Developmental disorders
Germline mutations in H3K4 methyltransferase genes cause developmental disorders. KMT2D mutations underlie Kabuki syndrome, a congenital condition with characteristic facial features, intellectual disability, and growth defects. Other COMPASS subunit genes, including KMT2A and KMT2B, have been linked to developmental and neurological phenotypes. These observations highlight the essential role of H3K4 methylation in normal development.
Neurological and neurodevelopmental conditions
H3K4 methylation is important for neural gene expression programs. Dynamic regulation of histone monoaminylation has been shown to influence neural rhythmicity, indicating that chromatin modifications including H3K4 methylation contribute to neuronal function. Mutations in KMT2 genes have been associated with neurodevelopmental disorders, further supporting a role for H3K4 methyltransferase activity in brain development and function.
Epigenetic therapy
Because H3K4 methyltransferases are druggable enzymes, they are candidates for epigenetic therapy. However, targeting histone lysine methylation is complicated by the redundancy of methyltransferases, the context-dependent effects of methylation, and the potential for toxicity. Preclinical studies continue to evaluate inhibitors and degraders of H3K4 methyltransferases in cancer models.
From histone H3K4 methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KMT2C alter H3K4 methylation and gene expression? | CRISPR knockout cell line |
| Does a specific KMT2D point mutation affect methyltransferase activity? | CRISPR point-mutation knock-in |
| How does a disease-associated mutation affect complex assembly? | Tagged knock-in of the catalytic subunit |
| Does overexpression of KMT2A drive oncogenic transcription? | CRISPR overexpression model |
| How does Caf1 regulate Ash1 activity? | Point-mutation and knockout of Caf1 |
| What is the genome-wide distribution of H3K4me3 after knockout? | Knockout followed by ChIP-seq |
How to Study the histone H3K4 methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide distribution of H3K4 methylation | Mapping promoters and enhancers |
| In vitro methyltransferase assay | Enzymatic activity toward histone substrates | Testing regulation by subunits |
| Mass spectrometry | Quantification of histone methylation states | Global changes after perturbation |
| RNA-seq | Transcriptional consequences of altered methylation | Gene expression profiling |
| CRISPR knockout | Loss-of-function effects on methylation and phenotype | Causal gene studies |
| CRISPR point mutation | Effect of specific amino acid changes on activity | Dissecting catalytic residues |
| CRISPR knock-in tagging | Localization and interaction of endogenous proteins | Complex assembly studies |
| CRISPR overexpression | Gain-of-function effects on chromatin and transcription | Oncogene modeling |
Chromatin immunoprecipitation sequencing (ChIP-seq)
ChIP-seq with antibodies against H3K4me1, H3K4me2, and H3K4me3 is the standard method for mapping the genomic distribution of these marks. High-resolution profiling in human cells has revealed distinct patterns at promoters and enhancers, providing a reference for studies of H3K4 methyltransferase activity. This method can be applied to knockout or mutant cell lines to determine how loss of a specific enzyme alters the epigenome.
In vitro methyltransferase assays
Recombinant or immunopurified complexes can be incubated with histone substrates and radiolabeled or fluorescent S-adenosyl-L-methionine to measure methyltransferase activity directly. Such assays have been used to demonstrate regulation of Ash1 by Caf1 and to study the effects of histone ubiquitination on methyltransferase activity. These experiments define the catalytic properties of the enzyme and its response to regulatory inputs.
Mass spectrometry-based proteomics
Mass spectrometry can quantify histone modifications, including mono-, di-, and trimethylation of H3K4, in cells and tissues. This approach complements antibody-based methods and can reveal global changes in methylation states upon genetic perturbation. Proteomics can also identify associated proteins in COMPASS-like complexes, helping to define the composition of the active enzyme.
CRISPR screening and functional genomics
Pooled CRISPR screens targeting H3K4 methyltransferase genes and their regulators can identify genes that modulate methylation-dependent phenotypes. Such screens are particularly useful for uncovering context-specific dependencies in cancer cells and for linking genotype to chromatin state. Combining screens with ChIP-seq and transcriptomics provides a systems-level view of H3K4 methyltransferase function.
How CRISPR Can Be Used to Study GO:0042800 histone H3K4 methyltransferase activity
Knockout
CRISPR knockout of H3K4 methyltransferase genes is used to eliminate enzymatic activity and assess downstream effects on H3K4 methylation, gene expression, and cellular phenotypes. For example, knockout of KMT2C has been used to study its tumor suppressor role and its impact on chromatin states. Knockout models are also valuable for testing redundancy among family members and for identifying context-specific dependencies.
Point Mutation
CRISPR point mutation enables the introduction of specific amino acid substitutions into catalytic or regulatory domains of H3K4 methyltransferases. This approach can separate catalytic activity from scaffolding functions and can model patient-derived mutations, such as those found in KMT2D in Kabuki syndrome. Point-mutation models are also useful for studying regulation by associated subunits, as illustrated by studies of Caf1 and Ash1.
Knock-in
CRISPR knock-in can be used to fuse tags or reporters to endogenous H3K4 methyltransferase genes, allowing visualization and biochemical isolation of the native complexes. Tagged knock-in models facilitate studies of complex assembly, subunit stoichiometry, and chromatin binding. Knock-in of disease-associated mutations can also create isogenic models for comparing mutant and wild-type enzyme function.
Overexpression
CRISPR overexpression models drive ectopic expression of H3K4 methyltransferases to test gain-of-function effects on chromatin and transcription. Overexpression of KMT2A and other family members has been used to model oncogenic roles and to identify downstream target genes. These models complement knockout studies by revealing whether increased enzyme dosage is sufficient to alter cellular phenotypes.
How EDITGENE Supports histone H3K4 methyltransferase activity Research
Researchers studying histone H3K4 methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific chromatin or disease phenotype. Establishing causality requires precise genetic tools that can remove, modify, or amplify the function of H3K4 methyltransferases and their regulators in relevant cell models. EDITGENE provides a comprehensive suite of CRISPR services designed to support such studies, from knockout and point-mutation models to knock-in reporters, overexpression lines, and library screening with bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for histone H3K4 methyltransferase activity research.
Frequently Asked Questions About histone H3K4 methyltransferase activity
What is histone H3K4 methyltransferase activity?
It is the enzymatic activity, annotated as GO:0042800, that transfers up to three methyl groups from S-adenosyl-L-methionine to lysine 4 of histone H3, producing S-adenosyl-L-homocysteine and mono-, di-, or trimethylated H3K4.
What genes are involved in histone H3K4 methyltransferase activity?
The main catalytic genes include KMT2A, KMT2B, KMT2C, KMT2D, KMT2E, KMT2F, KMT2G, and KMT2H, which encode SET-domain subunits of COMPASS-like complexes.
What is the difference between H3K4me1, H3K4me2, and H3K4me3?
These are the mono-, di-, and trimethylated forms of histone H3 lysine 4 generated by the same enzymatic activity. H3K4me3 is typically enriched at active promoters, while H3K4me1 is more prominent at enhancers.
Which diseases are linked to H3K4 methyltransferase mutations?
Mutations in KMT2C and KMT2D are linked to cancer, and KMT2D mutations cause Kabuki syndrome. Other KMT2 genes have been associated with developmental and neurological disorders.
How is H3K4 methyltransferase activity regulated?
It is regulated by core complex subunits such as WDR5, RBBP5, ASH2L, and DPY30, by histone ubiquitination, and by sensing of unmodified histone H3, as shown for Caf1 and Ash1.
What methods are used to study H3K4 methylation?
Common methods include ChIP-seq, in vitro methyltransferase assays, mass spectrometry, RNA-seq, and CRISPR-based genetic models.
Can CRISPR be used to study H3K4 methyltransferase function?
Yes. CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of H3K4 methyltransferases in chromatin regulation and disease.
What is the role of KMT2C in cancer?
KMT2C is frequently mutated in cancer and has been proposed to act as a tumor suppressor, with loss associated with altered chromatin and gene expression.
What is Kabuki syndrome and how does it relate to H3K4 methylation?
Kabuki syndrome is a developmental disorder often caused by mutations in KMT2D, which encodes an H3K4 methyltransferase, linking the disease to defective H3K4 methylation.
How does histone ubiquitination affect H3K4 methyltransferase activity?
Histone ubiquitination can modulate methyltransferase activity through diverse mechanisms, providing crosstalk between different chromatin modifications.
Conclusion
GO:0042800, histone H3K4 methyltransferase activity, represents a central enzymatic function in chromatin biology. It deposits mono-, di-, and trimethyl marks on histone H3 lysine 4, which are associated with active transcription and open chromatin. The activity is carried out by COMPASS-like complexes whose catalytic subunits are encoded by the KMT2 family and whose function is regulated by associated subunits and histone modifications. Dysregulation of H3K4 methyltransferases is linked to cancer, developmental disorders, and neurological conditions, making these enzymes important targets for both mechanistic and translational research. CRISPR-based models, combined with epigenomic and proteomic methods, provide powerful tools to dissect the causal roles of these enzymes and to evaluate therapeutic strategies.
References
- 1. Barski A et al.. 2007. High-resolution profiling of histone methylations in the human genome.. Cell 129(4):823-37 PMID: 17512414
- 2. Gold S et al.. 2024. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges.. J Clin Invest 134(20) PMID: 39403928
- 3. Zheng Q et al.. 2025. Bidirectional histone monoaminylation dynamics regulate neural rhythmicity.. Nature 637(8047):974-982 PMID: 39779849
- 4. Fields JK et al.. 2023. Diverse modes of regulating methyltransferase activity by histone ubiquitination.. Curr Opin Struct Biol 82:102649 PMID: 37429149
- 5. Yoon E et al.. 2023. Caf1 regulates the histone methyltransferase activity of Ash1 by sensing unmodified histone H3.. Epigenetics Chromatin 16(1):15 PMID: 37118845
- 6. Voichek Y et al.. 2018. Epigenetic Control of Expression Homeostasis during Replication Is Stabilized by the Replication Checkpoint.. Mol Cell 70(6):1121-1133.e9 PMID: 29910110
- 7. Jiao Y et al.. 2024. The modification role and tumor association with a methyltransferase: KMT2C.. Front Immunol 15:1444923 PMID: 39165358
- 8. Froimchuk E et al.. 2017. Histone H3 lysine 4 methyltransferase KMT2D.. Gene 627:337-342 PMID: 28669924
